Skip to main content

Advertisement

SpringerLink
Log in

Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

The objective of this study is to evaluate the safety of undiluted 0.5 % intracameral moxifloxacin for postoperative endophthalmitis prophylaxis in cataract surgery patients without the use of additional postoperative topical antibiotics. All phacoemulsification cataract surgeries performed by a single surgeon (B.A.) at the John A. Moran Eye Center from June 2012 to May 2015 were reviewed retrospectively. From June 2012 to April 2014, patients were given topical 0.5 % moxifloxacin postoperatively. From May 2014 to May 2015, all patients were given moxifloxacin intracamerally with no antibiotics postoperatively. The follow-up period was 1 month after surgery. Preoperative visual acuity and postoperative visual acuity, corneal edema, and anterior chamber reaction were recorded and compared between the two groups. 384 cataract surgeries were performed during the study period. None of the 384 eyes in the study developed endophthalmitis. Of those 384 eyes, 222 were included in the study for analysis based on the inclusion and exclusion criteria. 131 were part of the topical antibiotic group and 91 were part of the intracameral group. The differences in uncorrected visual acuity at 1 day postoperatively (p = 0.595) and best corrected visual acuity at 1 month postoperatively (p = 0.099) were not statistically significant. Differences in corneal edema (p = 0.370) and anterior chamber reaction (p = 0.069) at 1 day postoperatively and corneal edema (p = 0.512) and anterior chamber reaction (p = 0.512) at 1 month postoperatively were also not statistically significant. Undiluted 0.5 % moxifloxacin can be safely injected intracamerally following cataract surgery without additional postoperative antibiotic prophylaxis to prevent endophthalmitis without adverse effects on patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cullen K, Hall M, Golosinskiy A (2009) Ambulatory surgery in the United States, 2006. National health statistics reports

  2. Gore DM, Angunawela RI, Little BC (2009) United Kingdom survey of antibiotic prophylaxis practice after publication of the ESCRS Endophthalmitis Study. J Cataract Refract Surg 35(4):770–773. doi:10.1016/j.jcrs.2009.01.004

    Article  PubMed  Google Scholar 

  3. Kam JK, Buck D, Dawkins R, Sandhu SS, Allen PJ (2014) Survey of prophylactic intracameral antibiotic use in cataract surgery in an Australian context. Clin Exp Ophthalmol 42(4):398–400. doi:10.1111/ceo.12199

    Article  Google Scholar 

  4. Barry P (2014) Adoption of intracameral antibiotic prophylaxis of endophthalmitis following cataract surgery: update on the ESCRS Endophthalmitis Study. J Cataract Refract Surg 40(1):138–142. doi:10.1016/j.jcrs.2013.11.002

    Article  PubMed  Google Scholar 

  5. Chang DF, Braga-Mele R, Henderson BA, Mamalis N, Vasavada A, Committee ACC (2015) Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2014 ASCRS member survey. J Cataract Refract Surg 41(6):1300–1305. doi:10.1016/j.jcrs.2015.01.014

    Article  PubMed  Google Scholar 

  6. Endophthalmitis Study Group ESoC, Refractive S (2007) Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 33(6):978–988. doi:10.1016/j.jcrs.2007.02.032

    Article  Google Scholar 

  7. Delyfer MN, Rougier MB, Leoni S, Zhang Q, Dalbon F, Colin J, Korobelnik JF (2011) Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery. J Cataract Refract Surg 37(2):271–278. doi:10.1016/j.jcrs.2010.08.047

    Article  PubMed  Google Scholar 

  8. Seppala H, Al-Juhaish M, Jarvinen H, Laitinen R, Huovinen P (2004) Effect of prophylactic antibiotics on antimicrobial resistance of viridans streptococci in the normal flora of cataract surgery patients. J Cataract Refract Surg 30(2):307–315. doi:10.1016/S0886-3350(03)00617-5

    Article  PubMed  Google Scholar 

  9. Stroman DW, Dajcs JJ, Cupp GA, Schlech BA (2005) In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol 50(Suppl 1):S16–S31. doi:10.1016/j.survophthal.2005.06.002

    Article  PubMed  Google Scholar 

  10. Espiritu CR, Caparas VL, Bolinao JG (2007) Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 33(1):63–68. doi:10.1016/j.jcrs.2006.09.019

    Article  PubMed  Google Scholar 

  11. Matsuura K, Miyoshi T, Suto C, Akura J, Inoue Y (2013) Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan. J Cataract Refract Surg 39(11):1702–1706. doi:10.1016/j.jcrs.2013.05.036

    Article  PubMed  Google Scholar 

  12. Ekinci Koktekir B, Aslan BS (2012) Safety of prophylactic intracameral moxifloxacin use in cataract surgery. J Ocul Pharmacol Ther 28(3):278–282. doi:10.1089/jop.2011.0132

    Article  CAS  PubMed  Google Scholar 

  13. Lane SS, Osher RH, Masket S, Belani S (2008) Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg 34(9):1451–1459. doi:10.1016/j.jcrs.2008.05.034

    Article  PubMed  Google Scholar 

  14. Arbisser LB (2008) Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg 34(7):1114–1120. doi:10.1016/j.jcrs.2008.03.017

    Article  PubMed  Google Scholar 

  15. Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13(4):388–391

    CAS  PubMed  Google Scholar 

  16. Chen X, Adelman RA (2012) Microbial spectrum and resistance patterns in endophthalmitis: a 21-year (1988-2008) review in northeast United States. J Ocul Pharmacol Ther 28(4):329–334. doi:10.1089/jop.2011.0204

    Article  CAS  PubMed  Google Scholar 

  17. Matsuura K, Suto C, Akura J, Inoue Y (2013) Comparison between intracameral moxifloxacin administration methods by assessing intraocular concentrations and drug kinetics. Graefes Arch Clin Exp Ophthalmol 251(8):1955–1959. doi:10.1007/s00417-013-2294-7

    Article  CAS  PubMed  Google Scholar 

  18. Sharma T, Kamath MM, Kamath MG, Nayak RR, Bairy KL, Musmade PB (2015) Aqueous penetration of orally and topically administered moxifloxacin. Br J Ophthalmol. doi:10.1136/bjophthalmol-2014-306502

    Google Scholar 

  19. Robertson SM, Curtis MA, Schlech BA, Rusinko A, Owen GR, Dembinska O, Liao J, Dahlin DC (2005) Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 50(Suppl 1):S32–S45. doi:10.1016/j.survophthal.2005.07.001

    Article  PubMed  Google Scholar 

  20. Haas W, Pillar CM, Torres M, Morris TW, Sahm DF (2011) Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol 152(4):567–574 e563. doi:10.1016/j.ajo.2011.03.010

  21. Holland EJ, McDonald MB, Parekh JG, Sheppard JD (2014) Antibiotic resistance in acute postoperative endophthalmitis. Ophthalmology 121(11 Suppl):S1–S9 quiz S10–S12. doi:10.1016/j.ophtha.2014.06.049

  22. O’Brien TP, Arshinoff SA, Mah FS (2007) Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg 33(10):1790–1800. doi:10.1016/j.jcrs.2007.06.026

    Article  PubMed  Google Scholar 

  23. Olofsson SK, Cars O (2007) Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 45(Suppl 2):S129–S136. doi:10.1086/519256

    Article  CAS  PubMed  Google Scholar 

  24. Sharifi E, Porco TC, Naseri A (2009) Cost-effectiveness analysis of intracameral cefuroxime use for prophylaxis of endophthalmitis after cataract surgery. Ophthalmology 116(10):1887–1896 e1881. doi:10.1016/j.ophtha.2009.03.014

  25. Nguyen ET, Shorstein NH (2013) Preparation of intracameral antibiotics for injection. J Cataract Refract Surg 39(11):1778–1779. doi:10.1016/j.jcrs.2013.08.036

    Article  PubMed  Google Scholar 

  26. Lexicomp Online®, Lexi-Drugs®. Hudson, OH, USA: Lexi-Comp, Inc. Accessed 30 July 2015

  27. An JA, Kasner O, Samek DA, Levesque V (2014) Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg 40(11):1857–1861. doi:10.1016/j.jcrs.2014.02.037

    Article  PubMed  Google Scholar 

  28. Galvis V, Tello A, Sanchez MA, Camacho PA (2014) Cohort study of intracameral moxifloxacin in postoperative endophthalmitis prophylaxis. Ophthalmol Eye Dis 6:1–4. doi:10.4137/OED.S13102

    PubMed  PubMed Central  Google Scholar 

  29. Rudnisky CJ, Wan D, Weis E (2014) Antibiotic choice for the prophylaxis of post-cataract extraction endophthalmitis. Ophthalmology 121(4):835–841. doi:10.1016/j.ophtha.2013.08.046

    Article  PubMed  Google Scholar 

  30. Shorstein NH, Winthrop KL, Herrinton LJ (2013) Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg 39(1):8–14. doi:10.1016/j.jcrs.2012.07.031

    Article  PubMed  Google Scholar 

  31. Arshinoff SA, Bastianelli PA (2011) Incidence of postoperative endophthalmitis after immediate sequential bilateral cataract surgery. J Cataract Refract Surg 37(12):2105–2114. doi:10.1016/j.jcrs.2011.06.036

    Article  PubMed  Google Scholar 

  32. Friling E, Lundstrom M, Stenevi U, Montan P (2013) Six-year incidence of endophthalmitis after cataract surgery: Swedish national study. J Cataract Refract Surg 39(1):15–21. doi:10.1016/j.jcrs.2012.10.037

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Supported in part by an Unrestricted Grant from Research to Prevent Blindness, Inc., New York, NY, to the Department of Ophthalmology and Visual Sciences, University of Utah.

Funding

No author has a financial or proprietary interest in any material or method mentioned.

Author information

Authors and Affiliations

  1. John A. Moran Eye Center, University of Utah School of Medicine, 65 Mario Capecchi Drive, S5668, Salt Lake City, UT, 84132, USA

    Andrew Xingyu Zhou, Wyatt Boyer Messenger, Steven Sargent & Balamurali Krishna Ambati

Authors
  1. Andrew Xingyu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wyatt Boyer Messenger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven Sargent
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Balamurali Krishna Ambati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Balamurali Krishna Ambati.

Ethics declarations

Conflict of interest

The authors report no potential conflicts of interest. University of Utah Institutional Review Board approval was obtained.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, A.X., Messenger, W.B., Sargent, S. et al. Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery. Int Ophthalmol 36, 493–498 (2016). https://doi.org/10.1007/s10792-015-0151-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-015-0151-x

Keywords

Search

Navigation